Gemphire to Present at Two Investor Conferences
| Presentation Details 30th Annual ROTH Conference |
||
| Date: Time: Panel: Panelist: Location: |
Tuesday, March 13 7am Pacific Time/10am Eastern Time It Is Not a Myth, It Is Real: Pediatric NASH Seth Reno, Chief Commercial Officer Ritz Carlton, Laguna Niguel, California |
|
| Date: Time: Panel: Panelist: Location: |
Tuesday, March 13 8am Pacific Time/11am Eastern Time Love Your Liver, Love Your Heart: Cardio-Metabolic Molecules Steve Gullans, Ph.D., Interim Chief Executive Officer Ritz Carlton, Laguna Niguel, California |
|
| H.C. Wainwright 2nd Annual NASH Investor Conference | ||
| Date: Time: Presenter: Location: Webcast: |
Monday, March 19 8:40am Eastern Time Steve Gullans, Ph.D., Interim Chief Executive Officer St. Regis Hotel, New York City http://wsw.com/webcast/hcw3/gemp/ |
|
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
(646) 597-6987
(734)-245-1700